At the 2018 American Academy of Ophthalmology Annual Meeting in Chicago, IL, Patrik De Haes, MD, CEO of Oxurion (formerly ThromboGenics) spoke about several investigational molecules his company is investigating for various retina conditions.
Patrik De Haes, MD: What’s Coming Down the Retina Pipeline
By Michael Tattory|
2018-10-29T09:45:25-04:00
October 28th, 2018|News|Comments Off on Patrik De Haes, MD: What’s Coming Down the Retina Pipeline